Bleeding complications with PCI.
Satler LF.
Catheter Cardiovasc Interv. 2005 Mar;64(3):373-4. doi: 10.1002/ccd.20303.
[TAVI and coronary revascularization].
Combaret N, Bouchant M, Motreff P, Souteyrand G.
Ann Cardiol Angeiol (Paris). 2019 Dec;68(6):423-428. doi: 10.1016/j.ancard.2019.09.019. Epub 2019 Oct 21.
Drug-eluting stents.
Chieffo A, Colombo A.
Minerva Cardioangiol. 2002 Oct;50(5):419-29.
Bivalirudin: pharmacology and clinical applications.
Shammas NW.
Cardiovasc Drug Rev. 2005 Winter;23(4):345-60. doi: 10.1111/j.1527-3466.2005.tb00177.x.
Embolic protection devices in saphenous vein graft interventions.
Cragun DT, Heuser RR.
J Interv Cardiol. 2006 Dec;19(6):525-9. doi: 10.1111/j.1540-8183.2006.00204.x.
Clopidogrel before elective percutaneous coronary intervention.
Motovska Z, Widimsky P.
J Clin Pharmacol. 2010 Apr;50(4):373-9. doi: 10.1177/0091270009348975. Epub 2009 Sep 29.
Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis.
Nikolsky E, Mehran R, Halkin A, Aymong ED, Mintz GS, Lasic Z, Negoita M, Fahy M, Krieger S, Moussa I, Moses JW, Stone GW, Leon MB, Pocock SJ, Dangas G.
J Am Coll Cardiol. 2004 Sep 15;44(6):1200-9. doi: 10.1016/j.jacc.2004.06.048.
Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis.
Borentain M, Montalescot G, Bouzamondo A, Choussat R, Hulot JS, Lechat P.
Catheter Cardiovasc Interv. 2005 Jun;65(2):212-21. doi: 10.1002/ccd.20352.
Restenosis after PCI. Part 1: pathophysiology and risk factors.
Jukema JW, Verschuren JJ, Ahmed TA, Quax PH.
Nat Rev Cardiol. 2011 Sep 13;9(1):53-62. doi: 10.1038/nrcardio.2011.132.
Robotic-assist PCI: precision guided PCI or a rube goldberg solution?
Seto AH, Kern MJ.
Catheter Cardiovasc Interv. 2014 May 1;83(6):922-3. doi: 10.1002/ccd.25474.
